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Abstract A recombinant truncated form (A1-102/A428-452) of 
the non-heme iron-dependent metalloenzyme human phenylala-
nine hydroxylase (hPAH, phenylalanine 4-monooxygenase; EC 
1.14.16.1) was expressed in E. coli, purified to homogeneity as a 
homodimer (70 kDa) and crystallized using the hanging drop 
vapour diffusion method. The crystals are orthqrhombic, space 
group C222 with cell dimensions of a = 66.6 A, b = 108.4 A, 
c= 125.7 A. The calculated packing parameter (Vm) is 3.24 A
3 / 
Da with four 2-fold symmetric dimers (or eight momomers) in the 
unit cell. Data have been collected to 2.0 A resolution. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The non-heme iron-dependent metalloenzyme, mammalian 
phenylalanine hydroxylase (EC 1.14.16.1, phenylalanine 4-
monooxygenase (PAH)) catalyzes the hydroxylation of 1-phe-
nylalanine to L-tyrosine in the presence of 6(R)-L-erythro-
5,6,7,8-tetrahydrobiopterin and dioxygen, the intitial and 
rate-limiting step in the catabolism of this amino acid [1]. 
Phenylketonuria (PKU) is an autosomal recessive disease 
caused by mutat ions in the PAH gene [2], which results in a 
considerable heterogeneity both in terms of clinical, metabolic 
and enzymatic phenotypes [3]. More than 250 different P K U 
mutat ions have been reported [4]. Structural information on 
the human enzyme is greatly needed for a correlation between 
structure and function of this enzyme. P A H purified from rat 
liver (rPAH) is so far the best studied of all the pterin-depend-
ent hydroxylases, and preliminary data on its crystallization as 
a phosphorylated protein was reported 5 years ago [5]. Fur-
ther structural analysis of r P A H has not, however, been re-
ported, probably related to the occurrence of a molecular 
heterogeneity (tetramer < — > dimer equilibrium and different 
conformations as a result of a possible variable degree of 
enzyme phosphorylation). Our recent success in the large-scale 
production of recombinant human PAH (hPAH) has made it 
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Abbreviations: pPAH, human phenylalanine hydroxylase; wt-hPAH, 
wild-type human phenylalanine hydroxylase; (A1-102/A428-
452)hPAH, a truncated form of hPAH with a 102 amino-terminal 
deletion and a 24 carboxyl-terminal deletion; 6-BH4, 6(R)-L-erythro-
5,6,7,8-tetrahydrobiopterin; PEG, polythylene glycol; MBP, maltose 
binding protein; PKU, phenylketonuria 
possible to produce the non-phosphorylated forms of both the 
wild-type and mutan t forms in E. coli, using the p M A L ex-
pression vector [6,7]. In this paper, we report the overexpres-
sion, purification and crystallization of the truncated form of 
h P A H (A1-102/A428-452), recovered in high yield as a soluble 
dimeric protein of relative molecular mass 70 k D a and with a 
specific activity similar to the tetrameric wild-type enzyme 
(200 kDa) , as well as the diffraction analysis of native crystals. 
2. Experimental 
2.1. Materials 
IPTG and factor Xa were purchased from Boehringer-Mannheim 
(Germany). All other chemicals were obtained from Merck (Darm-
stadt, Germany). Polyethylene glycol 2000 and 4000 (PEG-2000 and 
PEG-4000) were obtained from Dow Chemicals (USA). For column 
chromatography a FPLC system (Pharmica, Uppsala, Sweden) was 
used [6]. The wild-type cDNA was subcloned into the pMAL-c2 vec-
tor (New England Biolabs), and the double deletion mutant form (Al-
102/A428-452)hPAH was prepared by PCR-based site-directed muta-
genesis as described [7,8]. 
2.2. Protein purification 
The fusion proteins MBP-(pepIEGR)Xa-hPAH and MBP-
(pepIEGR)Xa-(Al-102/A428-452)hPAH were expressed in the pMAL 
system of E. coli and purified as described [6]. The fusion proteins 
were cleaved by the restriction protease factor Xa and obtained in a 
highly purified form by high-performance size exclusion liquid chro-
matography. N-terminal amino acid sequence analysis was carried out 
using an ABI Model 477A automated sequencer following the man-
ufacturer's instructions. The protein was concentrated to 40-50 mg/ml 
by ultrafiltration (PLGC11K25 from Millipore Co., MA), gel-filtrated 
(prepacked NAP-5 column containing Sephadex G-25 Medium from 
Pharmica, Sweden) for solvent equilibration (see Section 3), and fur-
ther concentration to 15-25 mg/ml by ultrafiltration and subsequently 
used for crystallization. 
2.3. Crystallization 
For initial crystallization experiments an automated fast screening 
protocol was applied using the Imperial College automated crystalli-
zation device (IMPAX 1-5) [9,10] designed by Leslie Lloyd and Peter 
Brick (private communication). The microbatch droplet volumes were 
2.5 [il. Crystals were grown at 4°C, and the conditions that gave the 
best results were optimized. Final crystallization was carried out by 
the hanging-drop vapour diffusion technique at 4°C [11]. Droplets of 
10-12 ul initial volume were prepared on siliconized coverslips by 
mixing 5-6 ul protein solution and an equal volume of the reservoir 
solution and sealed against 0.8 ml of this solution. 
2.4. X-ray diffraction experiments 
Crystals were mounted in thin-walled glass capillaries with a small 
volume of reservoir solution. X-ray data were collected on the Swiss-
Norwegian beamline (BM1, Station A) at ESRF (Grenoble, France) 
using a 30 cm MAR image plate system (Mar Research). The data 
were collected at a wavelength of 0.873 A and crystal-to-detector 
distance of 25 cm. The exposure time was 60 s/l° frame and a total 
of 90 frames were collected. The intensities were indexed and inte-
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Fig. 1. A: Size-exclusion chromatography on a HiLoad Superdex column (1.6X60 cm) of the fusion protein of the double deletion mutant 
(A1-102/A428-452) of hPAH (5.2 mg) following cleavage with the restriction protease factor Xa. The column was equilibrated and eluted with 
20 mM Na-Hepes and 0.15 M NaCl, pH 7.0, at a flow rate of 0.38 ml/min. Detection at 280 nm. Peak positions: 196 min, homodimer of (Al-
102/A428-452)hPAH (70 kDa); 217 min, monomer of MBP (42.5 kDa). B: Rechromatography of (Al-102/A428-452)hPAH (1.8 mg) isolated in 
(A). The apparent molecular masses of the proteins were estimated using the elution position of the standard molecular mass proteins as a 
reference (see ref. [6]). 
grated using the program DENZO [12]. Scaling and merging were 
performed using the programs: ROT AVATA and SCALA from the 
CCP4 program package [13]. Structure factor amplitudes were calcu-
lated using the program TRUNCATE [13]. 
3. Results and discussion 
The overexpression in E. coli and purification yielded 100— 
150 mg of pure enzyme from 45 g wet cells. Size-exclusion 
chromatography revealed (Fig. 1) that the double deletion 
mutant exclusively exists as a homodimer of relative molec-
ular mass 70 kDa in solution, whereas the wt-hPAH is mainly 
a tetramer/dimer in equilibrium (data not shown) as reported 
previously [6,8]. N-terminal amino acid sequence analysis re-
vealed the expected sequence for both enzyme forms [6,8]. 
Their specific activity, when assayed with 100 |xM 6(R)-h-ery-
rtro-5,6,7,8-tetrahydrobiopterin as the cofactor after prein-
cubation with 1 mM L-phenylalanine [6,8], was 77.0 and 
80.0 nmol tyrosine min_1-nmol subunit-1 for the wt-hPAH 
and the (Al-102/A428-452)hPAH truncated form, respectively. 
The two enzyme forms (as isolated) contained 0.45 atoms of 
iron/subunit. The value is comparable to the =0.5 atom of 
iron/subunit found for recombinant rat PAH [14] and catalyti-
cally active iron in rat liver PAH [15,16]. 
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Fig. 2. Orthorombic crystal of the (Al-102/A428-452)pPAH homo-
dimer grown in 15-20% (w/v) PEG-2000, 0.06-0.08 M PIPES, pH 
6.8, at the estimated final protein concentration of 10-12 mg/ml. 
Crystal size is 2.0X0.7X0.2 mm3. 
Both proteins crystallize in the presence of PEG as the 
precipitating agent, and the best crystals were obtained at 
pH 6.5-7.2 (wild-type) and at pH 6.8 for the double deletion 
mutant, but the wild-type formed only microcrystals. Initially 
the screening conditions that gave small crystals of the trun-
cated form contained 25% (w/v) PEG-4000 buffered with 0.1 
M MES, pH 6.2 or 15-25% PEG-4000 buffered with 0.1 M 
PIPES, pH 6.8 at a protein concentration of 4 mg/ml. Larger 
crystals of the truncated form (thin plates of maximum size 
1.0 X 0.4 X 0.05 mm grew in 1 week) were obtained using PEG-
2000 (15-20%, w/v) buffered with 0.06-0.08 M PIPES, pH 6.8 
at a protein concentration of 3-6 mg/ml. Finally, orthorhom-
bic crystals with the same appearance as those produced by 
the microbath method, but dimensions up to 2.0X0.7X0.2 
mm3, were reproducibly grown in hanging drops within 2-3 
days using PEG-2000 (12-17%, w/v) buffered with 0.05-0.08 
M PIPES, pH 6.8 at a protein concentration of 10-12 mg/ml 
(Fig. 2). 
The crystals belong to the orthorhombic space group C222 
or C222i with a = 66.6 A, A = 108.4 A, c= 125.7 A. The Mat-
thews coefficient, Vm, assuming one monomer (35 kDa) in the 
asymmetric unit is calculated to be 3.24 A3/Da which corre-
sponds to a solvent content of 62% [17]. Combined with bio-
chemical evidence this suggest that the protein has crystallized 
as a perfect 2-fold symmetric dimer. The present dataset was 
collected to 2.0 A at room temperature and from one crystal, 
but diffraction was observed to about 1.8 A at a longer ex-
posure time than 60 s. Data collection and statistics are sum-
marized in Table 1. The dataset has a completeness of 97.3% 
Table 1 
Data collection statistics for the native data 
Resolution 
(A) 
28.37-4.91 
4.91-3.90 
3.90-3.41 
3.41-3.10 
3.10-2.88 
2.88-2.71 
2.71-2.57 
2.57-2.46 
2.46-2.36 
2.36-2.28 
2.28-2.21 
2.21-2.15 
2.15-2.09 
2.09-2.04 
2.04-1.99 
28.37-1.99 
Observations 
(n) 
2173 
2131 
2113 
2077 
2039 
2048 
2019 
2009 
2015 
2029 
2014 
2018 
2021 
2026 
1791 
30523 
Completeness 
(%) 
98 
99 
99 
99 
99 
98 
97 
97 
98 
97 
97 
98 
98 
98 
87 
97.3 
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between 28.37 and 2.04 A, with a total of 30 523 independent 
reflections. 
The determination of the crystal structure of hPAH will 
require the method of multiple isomorphous replacement, 
since our sequence alignment search with the hPAH sequence 
suggests no homology to any protein of known three-dimen-
sional structure. A number of potential heavy atom deriva-
tives have been investigated, but they are not fully isomor-
phous with the native protein and the search is continuing. 
Furthermore, we have produced a catalytically active seleno-
methionine-substituted form of the double deletion mutant, 
which has two methionines of the total 325 amino acids.The 
X-ray structure analysis of hPAH should provide insight into 
the catalytic mechanism of its enzymatic function as well as 
the structurally and functionally homologous enzymes tyro-
sine hydroxylase and tryptophan hydroxylase (for review, see 
[18]). Furthermore, it will represent an important frame of 
reference in the molecular characterization of the enzymatic 
phenotypes of the observed mutations in the hPAH [2,7,8] and 
human tyrosine hydroxylase [19,20] genes. 
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